Lexeo Therapeutics, Inc. - 8-K Filing
Lexeo Therapeutics reports positive interim Phase I/II data for LX2020 and Q3 2026 financial results showing $219.1 million in cash. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 8.01 below is attached as Exhibit 99, 9.01 Financial Statements and Exhibits)
Tickers: $LXEO